Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876798 | 0.82 | MEN1 (0.41) | MEN1KMT2AC5AR1TP53ALDH1A1 | |
| SCHEMBL28565840 | 0.80 | CYP1A2 (0.43) | TSHR | |
| SCHEMBL1044104 | 0.78 | LMNA (0.41) | IDO1TSHRL3MBTL1GRIN1GRIN2B | |
| SCHEMBL25971517 | 0.77 | EPHX2 (0.43) | TP53 | |
| SCHEMBL8990452 | 0.76 | TSHR (0.43) | KMT2AIDO1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL23581390 | 0.76 | SIGMAR1 (0.43) | MEN1KMT2AC5AR1ALDH1A1HTT | |
| SCHEMBL25518645 | 0.75 | EPHX2 (0.46) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL1044566 | 0.74 | PRMT5 (0.44) | IDO1ALDH1A1MAPT | |
| SCHEMBL1044704 | 0.74 | OPRL1 (0.55) | — | |
| Hydrochloric Acid SCHEMBL6524564 | 0.72 | OPRL1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271613-B1 | HYDROXYMETHYLCYCLOHEXYLAMINES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8288406-B2 | Hydroxymethylcyclohexylamines | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | Grünenthal GmbH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2271613-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009118171-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | OPRL1, OPRM1, OPRD1 | MEN1 3034/4885KMT2A 1124/4885IDO1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.